![Patient Looking Out Window](https://www.amcp.org/sites/default/files/styles/card_fullsize/public/images/patient-rare-disease-oncology.jpg.webp?itok=9GO-qVFl)
In a historic decision in December, the FDA approved the first gene therapy utilizing CRISPR, an innovative type of genome editing technology. This significant moment means that the novel therapy Casgevy is approved for the treatment of sickle cell disease—which affects 100,000 Americans—in patients 12 years of age and older.